AZD-5363, a kt inhibitor that binds to and inhibits all Akt isoforms, which showed favorable binding with LRRC41 in our study, were tested in a phase-I trial in advanced solid tumors, including HCC(Dean et al., 2018), showing acceptable safety and tolerability profiles. Here, AKT1 is linked to hepatocellular carcinoma.